CRIMINAL LAWAND PROCEDURE
320
drocodeinone, per 100 milliliters or not
more than 15 milligrams per dosage unit,
with a fourfold or greater quantity of an
isoquinoline alkaloid of opium (9805).
(4) Not more than 300 milligrams of dihy-
drocodeinone, per 100 milliliters or not
more than 15 milligrams per dosage unit,
with one (1) or more active nonnarcotic
ingredients in recognized therapeutic
amounts (9806).
(5) Not more than 1.8 grams of dihy-
drocodeine, per 100 milliliters or not more
than 90 milligrams per dosage unit, with
one (1) or more active, nonnarcotic ingre-
dients in recognized therapeutic amounts
(9807).
(6) Not more than 300 milligrams of eth-
ylmorphine, per 100 milliliters or not more
than 15 milligrams per dosage unit, with
one (1) or more active, nonnarcotic ingre-
dients in recognized therapeutic amounts
(9808).
(7) Not more than 500 milligrams of
opium per 100 milliliters or per 100 grams
or not more than 25 milligrams per dosage
unit, with one (1) or more active, nonnar-
cotic ingredients in recognized therapeu-
tic amounts (9809).
(8) Not more than 50 milligrams of mor-
phine, per 100 milliliters or per 100 grams
with one (1) or more active nonnarcotic
ingredients in recognized therapeutic
amounts (9810).
(9) Buprenorphine (9064).
(f) Anabolic steroid (as defined in 21 U.S.C.
802(41)(A) and 21 U.S.C. 802(41)(B)).
(g) The board shall except by rule any com-
pound, mixture, or preparation containing any
stimulant or depressant substance listed in sub-
sections (b) through (e) from the application of any
part of this article if the compound, mixture, or
preparation contains one (1) or more active medic-
inal ingredients not having a stimulant or depres-
sant effect on the central nervous system, and if
the admixtures are included therein in combina-
tions, quantity, proportion, or concentration that
vitiate the potential for abuse of the substances
which have a stimulant or depressant effect on the
central nervous system.
(h) Any material, compound, mixture, or
preparation which contains any quantity of
Ketamine (7285).
(i) Hallucinogenic substances:
Dronabinol (synthetic) in sesame oil and
encapsulated in a soft gelatin capsule in a
United States Food and Drug
Administration approved drug product
(7369).
35-48-2-9. Schedule IV tests.
(a) The board shall recommend placement of
a substance in schedule IV under this chapter if it
finds that:
(1) The substance has a low potential for
abuse relative to substances in schedule III
under this chapter;
(2) The substance has currently accepted
medical use in treatment in the United
States; and
(3) Abuse of the substance may lead to
limited physical dependence or psycho-
logical dependence relative to the sub-
stances in schedule III under this chapter.
(b) The board may recommend placement of
a substance in schedule IV under this chapter if it
finds that the substance is classified as a con-
trolled substance in schedule IV under federal
law.
35-48-2-10. Schedule IV.
(a) The controlled substances listed in this
section are included in schedule IV.
(b) Narcotic drugs. Unless specifically
excepted in a rule adopted by the board or unless
listed in another schedule, any material, com-
pound, mixture, or preparation containing any of
the following narcotic drugs, or their salts calcu-
lated as the free anhydrous base or alkaloid, in the
following limited quantities:
(1) Not more than 1 milligram of difenoxin
(9618) and not less than 25 micrograms of
atropine sulfate per dosage unit.
(2) Dextropropoxyphene (alpha- (+)-4-
dimethylamino-1,2- diphenyl-3-methyl-
2-propionoxybutane (9278).
(c) Depressants. Unless specifically excepted
in a rule adopted by the board or unless listed in
another schedule, any material, compound, mix-
ture, or preparation which contains any quantity
